Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11080-11090

  Ziegler, Susanne ^a,e   Skibbe, Kathrin ^a   Walker, Andreas ^a   Ke, Xiaoyu ^b   Heinemann, Falko M ^a   Heinold, Andreas ^a   Mok, Juk Yee ^c   van Esch, Wim J E ^c   Yang, Dongliang ^b   Wo¨lfl, Matthias ^d   Timm, Jo¨rg ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CENTRAL LABORATORY   (Netherlands)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; NONSTRUCTURAL PROTEIN 3; T LYMPHOCYTE RECEPTOR; EPITOPE; HLA A*02:01 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS ANTIGEN; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; ARTICLE; ASIA; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CROSS REACTION; EUROPE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; INTRAVENOUS DRUG ABUSE; NONHUMAN; NORTH AMERICA; PERIPHERAL BLOOD MONONUCLEAR CELL; SEQUENCE ANALYSIS; SERODIAGNOSIS; VIRUS CELL INTERACTION; VIRUS ISOLATION; AMINO ACID SEQUENCE; CELL CULTURE; CELLULAR IMMUNITY; CHEMISTRY; GENE EXPRESSION; GENETICS; HEPATITIS C; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULAR GENETICS; PROTEIN BINDING; SUBSTANCE ABUSE; VIROLOGY;

AMINO ACID SEQUENCE; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84906975967     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01590-14     Document Type: Article

References (38)

1. Callaway E. 2014. Hepatitis C drugs not reaching poor. Nature 508:295-296. http://dx.doi.org/10.1038/508295a.
2. Grebely J, Dore GJ. 2014. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 104:62-72. http://dx.doi.org/10.1016/j.antiviral.2014.01.002.
3. Bowen DG, Walker CM. 2005. Adaptive immune responses in acute and chronic hepatitisCvirus infection. Nature 436:946-952. http://dx.doi.org/10.1038/nature04079.
4. Timm J, Roggendorf M. 2007. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 13:4808-4817.
5. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep.26744.
6. Giugliano S, Oezkan F, Bedrejowski M, Kudla M, Reiser M, Viazov S, Scherbaum N, Roggendorf M, Timm J. 2009. Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3. Hepatology 50:707-716. http://dx.doi.org/10.1002/hep.23096.
7. Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmaurice K, Oniangue-Ndza C, Kemper MN, Humphreys I, McKiernan S, Kelleher D, Lohmann V, Bowness P, Huzly D, Rosen HR, Kim AY, Lauer GM, Allen TM, Barnes E, Roggendorf M, Blum HE, Thimme R. 2010. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology 51:54-62. http://dx.doi.org/10.1002/hep.23275.
8. z.astr57 and preservation of targeted epitopes. Gastroenterology 140:686-696.e1. http://dx.doi.org/10.1053/j.gastro.2010.09.042.
9. Ziegler S, Ruhl M, Tenckhoff H, Wiese M, Heinemann FM, Horn PA, Spengler U, Neumann-Haefelin C, Nattermann J, Timm J. 2013. Susceptibility to chronic hepatitis C virus infection is influenced by sequence differences in immunodominant CD8+ T cell epitopes. J. Hepatol. 58: 24-30. http://dx.doi.org/10.1016/j.jhep.2012.08.016.
10. Schmidt J, Neumann-Haefelin C, Altay T, Gostick E, Price DA, Lohmann V, Blum HE, Thimme R. 2011. Immunodominance of HLA-A2- restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency. J. Virol. 85:5232-5236. http://dx.doi.org/10.1128/JVI.00093-11.
11. Ward S, Lauer G, Isba R, Walker B, Klenerman P. 2002. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin. Exp. Immunol. 128:195-203. http://dx.doi.org/10.1046/j.1365-2249.2002.01840.x.
12. Wolfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li HM, Netski D, Ray SC, Pardoll D, Sidney J, Sette A, Allen T, Kuntzen T, Kavanagh DG, Kuball J, Greenberg PD, Cox AL. 2008. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181:6435- 6446. http://dx.doi.org/10.4049/jimmunol.181.9.6435.
13. Kuiken C, Hraber P, Thurmond J, Yusim K. 2008. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res. 36:D512-D516. http://dx.doi.org/10.1093/nar/gkm962.
14. Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefelin C, Chang DI, Klein M, Heinemann FM, Tenckhoff H, Wiese M, Horn PA, Viazov S, Spengler U, Roggendorf M, Scherbaum N, Nattermann J, Hoffmann D, Timm J. 2011. CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology 140:2064- 2073. http://dx.doi.org/10.1053/j.gastro.2011.02.060.
15. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, Schumacher TN. 2006. Design and use of conditional MHC class I ligands. Nat. Med. 12:246-251. http://dx.doi.org/10.1038/nm1360.
16. Wolfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD, Schlegel PG. 2011. Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol. Immunother. 60:173-186. http://dx.doi.org/10.1007/s00262-010-0928-8.
17. Wolfl M, Greenberg PD. 2014. Antigen-specific activation and cytokinefacilitated expansion of naive, human CD8+ T cells. Nat. Protoc. 9:950-966. http://dx.doi.org/10.1038/nprot.2014.064.
18. Roederer M, Nozzi JL, Nason MC. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79:167-174. http://dx.doi.org/10.1002/cyto.a.21015.
19. Yusim K, Dilan R, Borducchi E, Stanley K, Giorgi E, Fischer W, Theiler J, Marcotrigiano J, Korber B, Barouch DH. 2013. Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains. Clin. Vaccine Immunol. 20:302-305. http://dx.doi.org/10.1128/CVI.00605-12.
20. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, Shintani AK, Walker CM, Kalams SA. 2004. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J. Exp. Med. 200:307-319. http://dx.doi.org/10.1084/jem.20040638.
21. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price DA, Appay V. 2013. A molecular basis for the control of preimmune escape variants by HIVspecific CD8+T cells. Immunity 38:425-436. http://dx.doi.org/10.1016/j.immuni.2012.11.021.
22. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL, Walker CM. 2001. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15:883-895. http://dx.doi.org/10.1016/S1074-7613(01)00245-X.
23. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J, Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM. 2004. CD8 epitope escape and reversion in acuteHCVinfection. J. Exp. Med. 200:1593-1604. http://dx.doi.org/10.1084/jem.20041006.
24. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sidney J, Sette A, Pardoll D, Thomas DL, Ray SC. 2005. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201:1741- 1752. http://dx.doi.org/10.1084/jem.20050121.
25. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, Tavis JE, Rosen HR. 2005. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med. 201: 1725-1731. http://dx.doi.org/10.1084/jem.20042284.
26. Fytili P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, Zachou K, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H. 2008. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 26:3818-3826. http://dx.doi.org/10.1016/j.vaccine.2008.05.045.
27. Sewell AK. 2012. Why must T cells be cross-reactive? Nat. Rev. Immunol. 12:669-677. http://dx.doi.org/10.1038/nri3279.
28. Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. 2011. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J. Immunol. 187:2453-2463. http://dx.doi.org/10.4049/jimmunol.1101268.
29. Bulek AM, Cole DK, Skowera A, Dolton G, Gras S, Madura F, Fuller A, Miles JJ, Gostick E, Price DA, Drijfhout JW, Knight RR, Huang GC, Lissin N, Molloy PE, Wooldridge L, Jakobsen BK, Rossjohn J, Peakman M, Rizkallah PJ, Sewell AK. 2012. Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat. Immunol. 13:283-289. http://dx.doi.org/10.1038/ni.2206.
30. Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP, Dolton G, Clement M, Llewellyn-Lacey S, Price DA, Peakman M, Sewell AK. 2012. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 287: 1168-1177. http://dx.doi.org/10.1074/jbc.M111.289488.
31. Watson AM, Mylin LM, Thompson MM, Schell TD. 2012. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J. Immunol. 189:5549-5560. http://dx.doi.org/10.4049/jimmunol.1102221.
32. Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN. 2006. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 116:1382-1390. http://dx.doi.org/10.1172/JCI25591.
33. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, Kuntzen T, Fischer W, Nolan BE, Duncan J, Schulze zur Wiesch J, Kim AY, Frahm N, Brander C, Chung RT, Lauer GM, Korber BT, Allen TM. 2007. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 46:339-349. http://dx.doi.org/10.1002/hep.21702.
34. Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J. 2008. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J. Virol. 82:3438-3451. http://dx.doi.org/10.1128/JVI.01700-07.
35. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman P, Korber B, Kiepiela P, Walker B, Goulder P. 2005. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J. Exp. Med. 201:891-902. http://dx.doi.org/10.1084/jem.20041455.
36. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M, Goulder P. 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-645. http://dx.doi.org/10.1038/nature07746.
37. Munshaw S, Bailey JR, Liu L, Osburn WO, Burke KP, Cox AL, Ray SC. 2012. Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. J. Virol. 86:5915-5921. http://dx.doi.org/10.1128/JVI.05959-11.
38. Burke KP, Munshaw S, Osburn WO, Levine J, Liu L, Sidney J, Sette A, Ray SC, Cox AL. 2012. Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection. J. Immunol. 188:5177-5188. http://dx.doi.org/10.4049/jimmunol.1103008.